Spire Wealth Management’s Cardiff Oncology CRDF Stock Holding History

Spire Wealth Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$26K	–	2581
2021 Q4	$26K	Buy	+1,000	New	+$5.96K	﹤0.01%	2019

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Spire Wealth Management's CRDF Position: Q1 2022 in Review

Spire Wealth Management sold out of Cardiff Oncology (CRDF) in Q1 2022, closing a stake of 1,000 shares — an estimated $26K sold.

Spire Wealth Management first reported a position in CRDF in Q4 2021 and held it in 1 quarter. The position peaked at $26K in Q4 2021. 91 funds tracked by Wall St. Rank hold CRDF as of Q1 2022.

Spire Wealth Management reported no remaining Cardiff Oncology position as of Q1 2022 after selling out during the quarter.
Spire Wealth Management sold 1,000 Cardiff Oncology shares in Q1 2022, an estimated $26K.
Spire Wealth Management first reported a position in Cardiff Oncology in Q4 2021 and held it in 1 quarter.
Spire Wealth Management's Cardiff Oncology position peaked at $26K in Q4 2021.
91 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.